Harrow, Inc. (NASDAQ:HROW) Receives $61.40 Average PT from Analysts

Harrow, Inc. (NASDAQ:HROW - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $61.40.

HROW has been the topic of a number of research reports. B. Riley cut their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. William Blair began coverage on shares of Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating on the stock. BTIG Research began coverage on shares of Harrow in a research note on Thursday. They set a "buy" rating and a $62.00 price target on the stock. Finally, HC Wainwright lifted their price target on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th.

Harrow Trading Down 2.7%

Shares of HROW stock traded down $0.85 during mid-day trading on Thursday, reaching $30.31. The company's stock had a trading volume of 291,166 shares, compared to its average volume of 502,508. The company's 50 day simple moving average is $26.16 and its 200-day simple moving average is $29.51. Harrow has a 12-month low of $16.87 and a 12-month high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm has a market capitalization of $1.11 billion, a PE ratio of -32.24 and a beta of 0.40.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. On average, research analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Harrow in the 4th quarter worth about $25,000. Quarry LP bought a new stake in shares of Harrow in the 1st quarter worth about $32,000. Tower Research Capital LLC TRC increased its position in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Harrow in the 4th quarter worth about $78,000. Finally, State of Wyoming bought a new stake in shares of Harrow in the 1st quarter worth about $97,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.